SGLT 2 inhibitors: Antidiabetic agents with promising effects beyond glucose control

Abstract

Type 2 diabetes mellitus is a growing public health problem worldwide. It has a close relation with metabolic problems like obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular diseases. There are different antidiabetic agents being used in the treatment of diabetes mellitus with different mechanisms of action and a patient centered approach is required when choosing the appropriate treatment option. Sodium-glucose cotransporter (SGLT) 2 inhibitors also called glucoretics or gliflozins are members of a relatively new group of antidiabetic agents with promising cardioprotective and renoprotective effects beyond their glucose lowering efficacies.